ID: ALA5284854

Max Phase: Preclinical

Molecular Formula: C22H21NO3

Molecular Weight: 347.41

Associated Items:

Representations

Canonical SMILES:  O=C1/C(=C/c2ccc(N3CCCCC3)cc2)Cc2cc3c(cc21)OCO3

Standard InChI:  InChI=1S/C22H21NO3/c24-22-17(11-16-12-20-21(13-19(16)22)26-14-25-20)10-15-4-6-18(7-5-15)23-8-2-1-3-9-23/h4-7,10,12-13H,1-3,8-9,11,14H2/b17-10+

Standard InChI Key:  MFTXMRSWEYWASY-LICLKQGHSA-N

Associated Targets(Human)

A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CCD 19Lu (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PANC-1 (6144 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSL Tclin Cathepsin L (3852 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSD Tchem Cathepsin D (3201 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 347.41Molecular Weight (Monoisotopic): 347.1521AlogP: 4.23#Rotatable Bonds: 2
Polar Surface Area: 38.77Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 5.24CX LogP: 4.47CX LogD: 4.47
Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.76Np Likeness Score: -0.31

References

1. Altıntop MD, Özdemir A, Temel HE, Demir Cevizlidere B, Sever B, Kaplancıklı ZA, Akalın Çiftçi G..  (2022)  Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer.,  244  [PMID:36270087] [10.1016/j.ejmech.2022.114851]

Source